Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer.
Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of human breast cancers and has been shown to be accompanied by the overexpression of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of the first genetic alterations to be used clinically as a prognostic indicator, a predictive factor of response to doxorubicin (adriamycin) chemotherapy, and a test of patient eligibility for therapy with trastuzumab, a humanized anti-c-erbB-2 antibody. There are two types of tests to detect c-erbB-2 amplification/overexpression: immunohistochemistry and fluorescence in situ hybridization (FISH). Accurate identification of cases with c-erbB-2 amplification/overexpression requires an optimized combination of immunohistochemical and FISH tests.
Tsuda H
H
H
Pathology Division, National Cancer Center Research Institute, Japan.
D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D005260:Female; D005784:Gene Amplification; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D007124:Immunoenzyme Techniques; D009362:Neoplasm Metastasis; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015996:Survival Rate
D014408:Biomarkers, Tumor; D000090063:Proto-Oncogene Mas; D018719:Erb-b2 Receptor Tyrosine Kinases; C000715470:MAS1 protein, human